Yantai, China

Ling Wang

This inventor holds 1 USPTO granted patent. Top assignee: Remegen, Ltd.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ling Wang. Retrieved from https://idiyas.com/inventor/ling-wang-nrlv8qi8

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Ling Wang

Introduction

Ling Wang is a notable inventor based in Yantai, China. She has made significant contributions to the field of biotechnology, particularly in the development of innovative antibodies. Her work has the potential to impact various medical applications.

Latest Patents

Ling Wang holds a patent for an "ANTI-CLAUDIN 18.2 ANTIBODY AND ANTIBODY-DRUG CONJUGATE THEREOF." This invention represents a significant advancement in targeted therapies, showcasing her expertise and dedication to improving healthcare solutions. She has 1 patent to her name.

Career Highlights

Ling Wang is currently employed at Remegen Ltd., a company known for its focus on innovative biopharmaceuticals. Her role at Remegen allows her to work on cutting-edge research and development projects that aim to address unmet medical needs.

Collaborations

Ling Wang collaborates with esteemed colleagues, including Jianmin Fang and Yuanhao Li. These partnerships enhance her research efforts and contribute to the advancement of their shared goals in the field of biotechnology.

Conclusion

Ling Wang's contributions to the field of biotechnology through her innovative patent and collaborative efforts highlight her as a key figure in advancing medical science. Her work continues to inspire and pave the way for future innovations.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…